The expert committee of the European Medicines Agency (EMA) has assessed the effectiveness of current doses to combat the omicron variant. The first results warn that the african strain coronavirus could be tough to drugs.
However, the European Union agency has insisted that more studies are still needed to find out if pharmaceutical companies will eventually have to adapt vaccines.
On the other hand, Xevudy, an antiviral monoclonal antibody, will be considered by the EMA’s expert committee to combat COVID-19 in patients who do not require additional oxygen and who are at increased risk.
Recently, the UK Medicines and Healthcare Products Regulatory Agency (MHRA) became the first healthcare institution to approve the solution from the pharmaceutical companies GlaxoSmithKline (GSK) and Vir Biotechnology, which promises to be effective against the new omicron variant.
The EMA has also confirmed that it is likely that complete the Novavax assessment, for the production of your antigen from the anticovid vaccine, before the end of the year. “When authorized, this vaccine will provide a new option to immunize people in the European Union and around the world,” says the agency.
Vaccination in children
Regarding vaccination in children, the drug regulatory agency has confirmed that the data of drugs Pfizer Vaccine for 5-11-Year-Olds “Are Reassuring”. As he stressed, so far “no safety problem has arisen due to the large vaccination campaigns in this group in the United States.”
In this sense, the agency has clarified that, although immunization should be considered in all minors in this age group, those children at risk of severe coronavirus have special priority.